Secretion of Human Furin into Mouse Milk*

(Received for publication, March 18, 1997, and in revised form, April 9, 1997)

Rekha K. Paleyanda , Roman Drews , Timothy K. Lee and Henryk Lubon Dagger

From the J. Holland Laboratory, American Red Cross, Rockville, Maryland 20855

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

We have previously described the expression of the human proprotein convertase furin or paired basic amino acid-cleaving enzyme, in mice transgenic for paired basic amino acid-cleaving enzyme and human Protein C (HPC). Here we show 100-fold or higher expression of furin in the mammary gland, compared with endogenous furin. Furin and recombinant HPC were detected in the same regions of the mammary gland and regulated similar to the endogenous whey acidic protein. In addition to the expected intracellular localization, furin was secreted into the milk as an 80-kDa form lacking the transmembrane and cytoplasmic domains. Furin present at levels of up to 40,000 units/ml milk cleaved the t-butoxycarbonyl-RVRR-AMC substrate with a Km of 32 µM, and processed the recombinant HPC precursor at the appropriate sites. Surprisingly, the expression of an active protease was not toxic to the mammary gland. This is a rare example of an animal model secreting active truncated forms of a processing endoprotease into a bodily fluid.


INTRODUCTION

Furin or paired basic amino acid cleaving enzyme (PACE)1 is a Ca2+-dependent serine protease that processes proteins in the constitutive secretory pathway (1). Furin belongs to a family of subtilisin-like proprotein convertases including kexin (EC 3.4.21.61), PC1/3, PC2, PC4, PC5/6, PACE4 (reviewed in Ref. 1), and PC7/PC8 or lymphoma proprotein convertase (2-5), that play a role in the maturation of proproteins by cleavage at dibasic or tetrabasic sites (6). Unlike PC1/3, PC2, and PC4, which are restricted to endocrine, neural, or testicular germ cells and ovaries, respectively, the furin gene is expressed in most cells and tissues examined (1, 7).

cDNAs cloned from several species show furin to contain prepro-, catalytic and middle domains, a cysteine-rich region, transmembrane anchor, and cytoplasmic domain (1). Furin is activated by autocatalytic cleavage of its propeptide, presumably at the -Lys-Arg-Arg-Thr-Lys-Arg-1-down-arrow site (1, 8). A membrane-associated protein, it is found mainly in the trans-Golgi network (TGN) co-localized with the TGN 38 marker protein (9). Some amount of furin recycles between the cell surface and the TGN (9) in endosome-like structures (10). So far furin has not been detected in bodily fluids like blood, nor has the effect of its expression on cell and organ development been studied in transgenic animals.

Transgenic animals secreting recombinant proteins into milk, blood, urine, or saliva (11) have been generated and differences in recombinant protein modification compared with the human counterpart observed (12). In a pioneering attempt to engineer the post-translational capacity of the mouse mammary gland, we reported enhanced proteolytic maturation of the recombinant human Protein C (rHPC) precursor upon coexpression with furin (13). However, the effect of increased furin concentration on mammary gland development could not be predicted, nor its' intra- and extracellular distribution. Here we demonstrate localization of two heterologous proteins with the endogenous whey acidic protein (WAP) in the mouse mammary gland and secretion of active truncated furin into milk.


EXPERIMENTAL PROCEDURES

Transgene Construction and Generation of Transgenic Animals

The WAP/PACE construct comprising the 2.47-kb human furin cDNA and 74-base pair 3'-untranslated sequences, the four lines of CD-1 mice transgenic for WAP/HPC (12) and WAP/PACE expressing both transgenes in the mammary gland have been described (13).

Isolation and Northern Blotting of RNA

RNA was isolated from tissues of primiparous, F3 generation transgenic and control females on day 10 of lactation using RNAzol (Molecular Research Center). 15 µg of total RNA was fractionated on formaldehyde, 1.2% agarose gels along with RNA markers (Life Technologies) and transferred to GeneScreen Plus membranes (DuPont NEN). A radiolabeled 2.5-kb human PACE cDNA was used to detect mouse furin as they share 94% amino acid homology (14). Blots were hybridized under low stringency conditions, annealing at 62 °C and low stringency washing at 55 °C. Data were corrected for sample loading by ethidium bromide staining and 18 S rRNA detection.

Immunohistochemical Detection of Recombinant Proteins

Paraffin-embedded sections of mammary gland from mid-lactation bigenic mice were stained with hematoxylin/eosin or immunostained. Endogenous peroxidase activity was exhausted by immersion in 0.3% hydrogen peroxide for 30 min. Sections were preincubated in 1% bovine serum albumin in phosphate-buffered saline (PBS) with 10% rabbit, horse, or goat serum for the detection of rHPC, furin, or mWAP, respectively. Sections were reacted with a 1:400 dilution of sheep anti-HPC antibody (Affinity Biologicals), a 1:5 dilution of MON 148 antibody (gift of Dr. Van de Ven; Ref. 15) or a 1:800 dilution of rabbit anti-mWAP antibody (gift of Dr. Hennighausen), and developed with biotinylated secondary antibodies at 1:1000 to 1:2000 dilution, an ABC Elite kit (Vector Laboratories), DAB substrate (Sigma), and Mayer's hematoxylin as counterstain. Staining with secondary antibodies alone was negligible. Tissues of at least two animals from all four lines were analyzed.

Preparation of Milk and Western Blot Detection of Furin

Continuously bred mice of the F3 and F4 generations were milked between days 7 and 15 of lactation after intraperitoneal administration of 0.5 IU oxytocin (Sigma). Milk was diluted with 2 volumes of PBS, pH 7.4, containing 50 mM EDTA, centrifuged twice at 15,800 × g for 15 min at 4 °C, and stored at -80 °C. 20 µg of milk proteins were separated under reducing conditions on 8-16% (Novex) or 10% SDS-polyacrylamide gels and silver stained, or Western blotted with 1:20 to 1:100 dilutions of the MON 139, 148, 150, or 152 anti-furin monoclonal antibodies (15). Horseradish peroxidase-conjugated goat anti-mouse IgG at 0.5 µg/ml was added and blots developed by enhanced chemiluminescence (Amersham). rHPC was detected using the heavy chain-specific 8861 monoclonal antibody, or a sheep polyclonal antibody. Milk was fractionated essentially as described (16, 17). Briefly, 100 µl of whole milk containing sucrose at 5% (w/v) was underlaid beneath 1 ml of PBS and spun at 1,500 × g, for 30 min at 22 °C. A lower "skim milk" fraction was collected, while the upper fat fraction was diluted in 1 ml of PBS and respun. A lower "cream wash" fraction was collected, while fat globules were dispersed in 1.3 ml of 0.05 M Tris, pH 7.5, with 0.15 M NaCl, 0.1% (v/v) SDS, 1% (v/v) Triton X-100, and 1% (w/v) sodium deoxycholate. Globules were chilled to 4 °C and spun at 50,000 × g, for 60 min. The milk fat globule membrane (MFGM) "supernatant" was collected and the "MFGM pellet" resuspended in buffer. Fractions were analyzed by 8% SDS-PAGE.

Activity of Furin in Milk

Fluorometric assays were carried out essentially as described (18). Defatted milk diluted 1:100 to 1:400 was incubated for 5 min at 37 °C with an equal volume of 100 µM peptide substrate Boc-RVRR-AMC (N-alpha -t-butoxycarbonyl-L-arginyl-L-valyl-L-arginyl-L-arginine-7-AMC; Bachem) in 100 mM HEPES, pH 7.5, containing 1 mM CaCl2 and 0.5% Triton X-100, in a 200-µl volume. Reactions were terminated by the addition of 100 µl of 15 mM EDTA. 7-Amino-4-methylcoumarin (AMC) liberated by cleavage was measured with a Perkin-Elmer LS-3 spectrofluorometer, 380 nm excitation, 460 nm emission. The blank sample consisted of substrate alone, while control milk values were negligible. For kinetic analysis, duplicate milk samples diluted 1:200 were incubated for 5 min with Boc-RVRR-AMC at concentrations ranging from 12.5 to 200 µM. Protease activity was assessed by incubating whole mouse milk from the HPC line 6.4 (12) in a 10:1 ratio with milk from HPC/PACE line C5.2, for 0-30 min at 37 °C. Milk was then diluted and processed with PBS, pH 7.4, with 50 mM EDTA to inhibit further furin activity.

Purification of rHPC Processed by Secreted Furin

Whole milk, from the HPC line 6.4, 0.9 ml, was incubated with 0.1 ml of milk from line C5.2 HPC/PACE mice for 3 h, at 37 °C. Milk was diluted with 20 ml of 50 mM Tris, 0.15 M NaCl, 2 mM EDTA, 2 mM benzamidine, pH 7.2, and centrifuged at 30,000 × g for 15 min at 4 °C. The defatted milk was re-centrifuged, filtered, and rHPC purified as described (13).


RESULTS

Expression of Furin Transgene in Bigenic Mice

Northern blot hybridization with the human probe under conditions of low stringency revealed a 4.2-kb furin transcript in control and transgenic mouse mammary glands, Fig. 1, corresponding to reports of a 4.5-kb RNA in mouse kidney (7) and a 4.0-kb RNA in other tissues (14). The signal obtained in the mammary gland was 5-10-fold lower than that in the liver, salivary gland, and brain (data not shown). The expected 2.5-kb human furin transcript was detected in bigenic mice at levels about 100-fold higher than endogenous furin.


Fig. 1. Northern blot analysis of furin expression in the mammary gland. Total RNA from tissues taken at mid-lactation was electrophoresed at 15 µg/lane. A 4.2-kb endogenous mouse furin transcript was detected by a human furin cDNA probe (lane 1), after a 3-day exposure. The 2.5-kb transgene RNA was observed in transgenic tissue (lane 2), but not in control. RNA molecular weight standards are on the left.
[View Larger Version of this Image (26K GIF file)]

Detection of Recombinant Proteins in the Mammary Gland

Histologic analyses of the mammary glands of HPC/PACE bigenic mice did not reveal differences in their gross morphology compared with control mice, Fig. 2. Transgenic tissues differed subtly, having less distended alveoli with larger epithelial cells, as in HPC transgenic mice (19). The distribution of recombinant proteins and endogenous WAP was compared by immunostaining of serial sections. rHPC was found in the secretory epithelium, and alveolar and ductal lumina. Unlike the relatively diffuse intracellular staining pattern of WAP and rHPC, furin showed a more discrete staining pattern. Unexpectedly, furin was also detected in the lumen, indicating secretion from the apical surface of epithelial cells. WAP, rHPC, and furin were detected in all the alveoli and ducts, although some alveoli stained more intensely than others. Furin and rHPC synthesis appeared to be regulated like WAP, being present inside the epithelial cells lining collapsed milked-out alveoli, although predominantly in the lumina of milk-distended alveoli. Control mouse tissue was stained neither by furin- nor rHPC-specific antibodies.


Fig. 2. Immunohistochemical localization of furin in the mammary gland. Paraffin-embedded serial sections of mammary gland from WAP/HPC bigenic mouse C5.2.4.23.2 at mid-lactation were stained with hematoxylin/eosin (A) or immunostained by the indirect immunoperoxidase technique. mWAP was detected with a rabbit anti-mouse WAP antibody (B), rHPC with a sheep anti-HPC antibody (C and E), and furin with the MON 148 antibody (D and F). Furin is present in the alveolar lumina and within epithelial cells, similar to rHPC and mWAP. The short arrow marks the same alveolus in different sections, while the boxed regions in C and D (100 ×) are enlarged in E and F (400 ×). The long arrow denotes discrete intracellular staining of furin.
[View Larger Version of this Image (158K GIF file)]

Characterization of Furin Secreted in Milk

The furin-specific MON 148 antibody (15) detected a protein of approximately 80 kDa in bigenic mouse milk, which was absent in control milk (Fig. 3A). Higher levels were detected in lines C1.2, C2.2, and C5.2, than in C4.1. Trace polypeptides of approximately 150 kDa were also detected. A 141-kDa membrane-associated form of furin was recently reported in neural lobe secretory vesicles (20). MON 152 which is specific for human furin also detected the 80-kDa protein (Fig. 3B). The enzyme was not recognized by MON 150 and MON 139, indicating removal of the propeptide and C-terminal region, respectively (Fig. 4). These results are consistent with truncation at the hydrophobic transmembrane domain, resulting in secretion of an 80-kDa form. The minor protein species of approximately 65 kDa probably arises from additional cleavage(s) in the cysteine-rich region (21, 22). Selective inclusion of furin in the MFGM was not observed upon fractionation of milk (Fig. 3C), while traces of a 90-kDa protein detected upon prolonged exposure may represent full-length furin from sloughed-off epithelial cells. A rough estimate of 81-325 µg/ml furin in the milk was obtained by comparison with Coomassie Blue-stained gels and Western blots of soluble furin secreted by CV-1 cells (data not shown).


Fig. 3. Western blot of furin secreted into milk. Milk proteins were separated by SDS-PAGE in 8% gels under reducing conditions. A, blot of milk proteins from two control mice (CON) and from HPC/PACE transgenic mice from lines C1.2, C2.2, C4.1, and C5.2 was probed with a 1:100 dilution of MON 148. B, milk proteins from control and line C5.2 mice were Western blotted with the monoclonal antibodies MON 139, 148, 150, and 152 at a 1:20 dilution, as marked. C, furin was detected in different fractions such as the milk fat globule membrane (MFGM) supernatant (lane 1), MFGM pellet (lane 2), cream wash (lane 3), and skim milk (lane 4) from a C5.2 mouse, using a 1:100 dilution of MON 148 antibody. No furin was detected in control skim milk (lane 5). Positions of molecular weight markers are shown on the left. Mouse IgG (H) chains are detected by the secondary antibodies at 50 and 100 kDa.
[View Larger Version of this Image (22K GIF file)]


Fig. 4. Processing of rHPC and furin in the mammary gland. The WAP/HPC and WAP/PACE transgenes were coexpressed in the mouse mammary gland. Pro-furin composed of the propeptide (P), serine protease (SP), middle (M), Cys-rich (CYS), transmembrane (TM), and cytoplasmic (C) domains is activated by propeptide cleavage. Furin is localized to the TGN or undergoes C-terminal truncation and is secreted into the milk. Furin processes pro-Protein C inside cells to the mature form by removing the propeptide and the internal dipeptide. Processing may also continue in milk. The arrows denote known proprotein cleavage sites, while the dotted arrows indicate probable cleavage sites. The thin bars define the epitopes recognized by MON 139, 148, 150, and 152 antibodies, the darker bars the predicted antigenic regions (15).
[View Larger Version of this Image (17K GIF file)]

Activity of Secreted Furin

Release of AMC from a fluorogenic tetrapeptide substrate, Boc-RVRR-AMC, indicated the presence of active furin in milk. The activity of furin varied in four lines of mice correlating with mRNA (13) and protein levels (Table I and Fig. 3A). Secreted furin cleaved the substrate with an average Km of 32.3 ± 0.85 µM, correlating with the reported values of 27 and 26 µM for furin secreted from VV:hFUR (23) and hFUR713t-infected BSC40 cells (18), respectively, and indicating similarity of the serine protease domains.

Table I. Activity of furin in bigenic mouse milk

The activity of secreted furin was determined by cleavage of a fluorogenic substrate. One unit of activity was defined as the amount of enzyme required to liberate 1 pmol of AMC from Boc-RVRR-AMC per min. Assays were performed in triplicate. Km values were calculated from Lineweaver-Burk plots of initial velocity measured at different substrate concentrations.

Mouse line Activity in milk Michaelis constant, Km

units/ml µM
C 1.2 21,973  ± 724 32.26
C 2.2 27,470  ± 1,668 33.33
C 4.1 10,902  ± 359 32.15
C 5.2 40,515  ± 706 31.25

In HPC/PACE bigenic mice, rHPC was processed to the mature protein (13), unlike rHPC from HPC transgenic mice, which consisted mainly of the single chain precursor with propeptide (12). Incubating the milk of bigenic and HPC mice together resulted in a reduction of the amount of rHPC single chain (Fig. 5A and Fig. 4). Incubation of milk from HPC mice alone did not alter the electrophoretic pattern of rHPC, but trace amounts of single chain present in HPC/PACE milk disappeared. rHPC purified from a mixture of HPC/PACE and HPC milk after incubation showed a marked reduction in the amount of precursor (Fig. 5B). Amino acid sequencing confirmed site-specific cleavage of the propeptide.


Fig. 5. Protease activity of secreted furin. A, milk from HPC/PACE mice, HPC mice, or a 1:10 mixture of milk from HPC/PACE and HPC mice, was incubated at 37 °C for 0 (lanes 1, 3, 5, 7, and 9) to 30 min (lanes 2, 4, 6, 8, and 10). Milk was then diluted in PBS containing EDTA, defatted, and 20 µg of reduced proteins resolved on 8-16% gels. Western blot detection of rHPC was carried out using the 8861 monoclonal antibody (lanes 1-6) or the sheep polyclonal antibody (lanes 7-10). The dot indicates a mouse protein recognized by the goat anti-mouse secondary antibody (lanes 1-6). B, rHPC was purified from a mixture of HPC/PACE and HPC mouse milk after incubation for 3 h at 37 °C, by immunoaffinity chromatography using the 8861 antibody and resolved by 8-16% SDS-PAGE. Western blots were probed with the sheep anti-HPC antibody. rHPC purified from the milk of HPC/PACE mice, line C5.2 (lanes 1 and 2), from HPC transgenic mice (lanes 3 and 4), and from the mixture of HPC and HPC/PACE mouse milk (lanes 5 and 6), plasma-derived HPC (lane 7). SC, single chain; HC, heavy chain; LC, light chain. alpha -, beta -, gamma -HC represent HC glycoforms.
[View Larger Version of this Image (45K GIF file)]


DISCUSSION

Normal cells express furin at low levels and the enzyme is ubiquitously distributed (7). Expression of furin in genetically engineered cells or animals at a great excess beyond the basal level deviates from the physiological norm and may be toxic. Toxicity of furin has been reported in transfected cells (24), probably due to broadened specificity. The furin gene was also up-regulated 5-10-fold in primary human non-small cell lung carcinomas (7), while PC7/PC8 has been implicated as a target for chromosomal translocation and deregulation (5). Various proteins involved in mammary growth and differentiation like insulin (25), insulin-like growth factor (6), insulin pro-receptor (26), transforming growth factor-beta 1 (27), and parathyroid hormone-related protein (22) are also processed by furin. Stromelysin-3, a metalloprotease involved in mammary tissue remodeling, was activated by furin in cells and in solution (29). Thus, undesirable effects following the expression of an additional protease could not be excluded. We show here that although transgene transcripts were highly expressed, mammary gland gross morphology was similar in normal and transgenic animals. Mammary development was not impaired, nor were tumors observed in mice from any line for up to 2 years of age and over several generations, implying that increased furin expression in mammary epithelial cells was not associated with transformation. Our results also do not implicate secreted furin in tissue remodeling.

Two mechanisms could possibly explain our data. First, large amounts of the specific substrate, rHPC, may limit access of furin to other proteins. The presence of furin and rHPC in the same region of the mammary gland and in the same alveoli would support this argument. Our unique observation of the co-localization of two foreign proteins suggests the coordinated regulation of expression and protein synthesis of two cointegrated transgenes in the mammary gland. The two transgenes under control of the 4.1-kb WAP promoter also mimicked the pattern of synthesis of endogenous WAP, supporting reports of the simultaneous synthesis of endogenous milk proteins and a heterologous protein under the control of the beta -lactoglobulin promoter (30). Although several multigenic animal models have been generated, the site(s) of synthesis and cellular distribution of foreign proteins were not established (31, 32). The amount of fully assembled human fibrinogen hexamer secreted into milk of beta -lactoglobulin/fibrinogen transgenic mice was reported to range from 10 to 100% (32). As coordinate synthesis of the alpha -, beta -, gamma -subunit chains is required for the correct assembly of human fibrinogen, partial assembly may imply a heterogeneous pattern of synthesis in some lines.

The second mechanism assumes secretion of excess furin from epithelial cells (Fig. 4). Secretion from transfected cells (23, 33, 34) has been suggested as a mechanism to regulate the amount of intracellular enzyme (35) and we also detected furin in milk. So far furin had not been detected in any bodily fluid in normal or pathological states, probably due to the low sensitivity of existing methods. This should be considered when generating animals expressing furin in the liver, as the secreted protein could be directed to the circulation. We had expected furin to be shed from the apical plasma membrane of mammary cells in fat globules, but did not detect full-length protein in the MFGM fraction. Unlike the cystic fibrosis transductance regulator protein found predominantly in the milk fat of transgenic mice (19), this was not the main route of furin secretion. Finding truncated furin in all fractions of milk suggested secretion along with the milk proteins. Propeptide removal probably occurred in the endoplasmic reticulum, followed by targeting to the TGN in the presence of the cytoplasmic tail (9, 33). Cleavage of the acidic signal crucial for TGN retention then resulted in secretion (28, 29), implying that C-terminal processing of furin occurs in normal, untransformed mammalian cells.

The activity of secreted furin provided further evidence of propeptide processing, as propeptide removal was necessary for enzyme activation (9) and the presence of propeptide on a furin mutant led to loss of activity (36). In milk up to 40,000 units/ml active furin which functioned as a protease in the maturation of the rHPC precursor was detected, unlike the PACE-Sol mutant which was unable to process vWF in the medium of COS-1 cells (37). We therefore conclude that both the intracellular and truncated extracellular forms are active and process the rHPC precursor in epithelial cells as well as in milk (Fig. 4). Similarly, Prieto et al. (1995) described the presence of active human alpha 1,2-fucosyltransferase in the milk of mice (38). Thus, it is possible to produce significant amounts of secreted forms of intracellular enzymes in milk.

Our results should encourage others to augment the processing of endogenous and heterologous proteins in transgenic animals. It will not be necessary to process incompletely modified recombinant proteins in vitro, instead this can be done simultaneously in vivo. The intra- and extracellular presence of furin allows for multiple interactions with its substrate, thus removing temporal and spatial constraints on proprotein processing and highlighting further advantages of protein production in transgenic animal bioreactors.


FOOTNOTES

*   The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    To whom correspondence should be addressed: 15601 Crabbs Branch Way, Rockville, MD 20855. Tel.: 301-738-0782; Fax: 301-738-0708; E-mail: lubon{at}usa.redcross.org.
1   The abbreviations used are: PACE, paired basic amino acid-cleaving enzyme; TGN, trans-Golgi network; WAP, whey acidic protein; rHPC, recombinant human Protein C; kb, kilobase pairs; PAGE, polyacrylamide gel electrophoresis; MFGM, milk fat globule membrane; Boc, t-butoxycarbonyl; AMC, 7-amino-4-methyl coumarin.

ACKNOWLEDGEMENTS

We thank Drs. R. J. Kaufman and A. Rehemtulla for the human PACE/furin cDNA clone, Dr. W. J. M. van de Ven for the generous gift of the MON 139, 148, 150, and 152 antibodies, Dr. L. Hennighausen for the anti-WAP antibody, Dr. C. Haudenschild for help with immunohistochemistry, and Dr. W. Garten for partially purified soluble furin from CV-1 cells. We are grateful to Dr. W. N. Drohan for continued support.


REFERENCES

  1. van de Ven, W. J. M., Roebroek, A. J. M., and van Duijnhoven, H. L. P. (1993) Crit. Rev. Oncog. 4, 115-136 [Medline] [Order article via Infotrieve]
  2. Seidah, N. J., Hammelin, J., Mamarbachi, M., Dong, W., Tadros, H., Mbikay, M., Chretien, M., and Day, R. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 3388-3393 [Abstract/Free Full Text]
  3. Constam, D. B., Calfon, M., and Robertson, E. J. (1996) J. Cell Biol. 134, 181-191 [Abstract]
  4. Bruzzaniti, A., Goodge, K., Jay, P., Taviaux, S. A., Lam, M. H. C., Berta, P., Martin, T. J., Moseley, J. M., and Gillespie, M. T. (1996) Biochem. J. 314, 727-731 [Medline] [Order article via Infotrieve]
  5. Meerabux, J., Yaspo, M-L., Roebroek, A. J., Van de Ven, W. J. M., Lister, A., and Young, B. D. (1996) Cancer Res. 56, 448-451 [Abstract]
  6. Barr, P. J. (1991) Cell 66, 1-3 [Medline] [Order article via Infotrieve]
  7. Schalken, J. A., Roebroek, A. J. M., Oomen, P. P. C. A., Wagenaar, S. Sc., Debruyne, F. M. J., Bloemers, H. P. J., and Van de Ven, W. J. M. (1996) J. Clin. Invest. 80, 1545-1549
  8. Creemers, J. W. M., Vey, M., Schäfer, W., Ayoubi, T. A. Y., Roebroek, A. J. M., Klenk, H-D., Garten, W., and Van de Ven, W. J. M. (1995) J. Biol. Chem. 270, 2695-2702 [Abstract/Free Full Text]
  9. Molloy, S. S., Thomas, L., VanSlyke, J. K., Stenberg, P. E., and Thomas, G. (1994) EMBO J. 13, 18-33 [Abstract]
  10. Sariola, M., Saraste, J., and Kuismanen, E. (1995) J. Cell Sci. 108, 2465-2475 [Abstract/Free Full Text]
  11. Lubon, H., Paleyanda, R. K., Velander, W. H., and Drohan, W. N. (1995) Transfus. Med. Rev. X, 131-143
  12. Drohan, W., Zhang, D-W., Paleyanda, R., Chang, R., Wroble, M., Velander, W., and Lubon, H (1994) Transgenic Res. 3, 355-364 [Medline] [Order article via Infotrieve]
  13. Drews, R., Paleyanda, R. K., Lee, T. K., Chang, R. R., Drohan, W. N., and Lubon, H. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 10462-10466 [Abstract]
  14. Hatsuzawa, K., Hosaka, M., Nakagawa, T., Nagase, M., Shoda, A., Murakami, K., and Nakayama, K. (1990) J. Biol. Chem. 265, 22075-22078 [Abstract/Free Full Text]
  15. van Duijnhoven, H. L. P., Creemers, J. W. M., Kranenborg, M. G. C., Timmer, E. D. J., Groeneveld, A., van den Ouweland, A. M. W., Roebroek, A. J. M., and van de Ven, W. J. M. (1992) Hybridoma 11, 71-86 [Medline] [Order article via Infotrieve]
  16. Patton, S., and Huston, G. E. (1986) Lipids 21, 170-174 [Medline] [Order article via Infotrieve]
  17. DiTullio, P., Cheng, S. H., Marshall, J., Gregory, R. J., Ebert, K. M., Meade, H. M., and Smith, A. E. (1992) Bio/Technology 10, 74-77 [Medline] [Order article via Infotrieve]
  18. Molloy, S. S., Bresnahan, P. A., Leppla, S. H., Klimpel, K. R., and Thomas, G. (1992) J. Biol. Chem. 267, 16396-16402 [Abstract/Free Full Text]
  19. Paleyanda, R. K., Zhang, D-W., Hennighausen, L., McKnight, R., Drohan, W. N., and Lubon, H. (1994) Transgenic Res. 3, 335-343 [Medline] [Order article via Infotrieve]
  20. Hill, R. M., Ledgerwood, E. C., Brennan, S. O., Pu, L.-P., Loh, Y. P., Christie, D. L., and Birch, N. P. (1995) J. Neurochem. 65, 2318-2326 [Medline] [Order article via Infotrieve]
  21. Munzer, J. S., Jean, F., Basak, A., Lazure, C., Thomas, G., and Seidah, N. (1995) J. Cell. Biochem. Suppl. 19B, B7-108
  22. Bravo, D. A., Gleason, J. B., Sanchez, R. I., Roth, R. A., and Fuller, R. S. (1994) J. Biol. Chem. 269, 25830-25837 [Abstract/Free Full Text]
  23. Vidricaire, G., Denault, J-B., and Leduc, R. (1993) Biochem. Biophys. Res. Commun. 195, 1011-1018 [CrossRef][Medline] [Order article via Infotrieve]
  24. Ayoubi, T. A. Y., Creemers, J. W. M., Roebroek, A. J. M., and Van de Ven, W. J. M. (1994) J. Biol. Chem. 269, 9298-9303 [Abstract/Free Full Text]
  25. Brennan, S. O., and Peach, R. J. (1991) J. Biol. Chem. 266, 21504-21508 [Abstract/Free Full Text]
  26. Bravo, D. A., Gleason, J. B., Sanchez, R. I., Roth, R. A., and Fuller, R. S. (1994) J. Biol. Chem. 269, 25830-25837 [Abstract/Free Full Text]
  27. Dubois, C. M., Laprise, M-H., Blanchette, F., Gentry, L. E., and Leduc, R. (1995) J. Biol. Chem. 270, 10618-10624 [Abstract/Free Full Text]
  28. Liu, B., Amizuka, N., Goltzman, D., and Rabbani, S. A. (1995) Int. J. Cancer 63, 276-281 [Medline] [Order article via Infotrieve]
  29. Pei, D., and Weiss, S. J. (1995) Nature 375, 244-247 [CrossRef][Medline] [Order article via Infotrieve]
  30. Faerman, A., Barash, I., Puzis, R., Nathan, M., Hurwitz, D. R., and Shani, M. (1995) J. Histochem. Cytochem. 43, 461-470 [Abstract/Free Full Text]
  31. McKnight, R. A., Wall, R. J., and Hennighausen, L. (1995) Transgenic Res. 4, 39-43 [Medline] [Order article via Infotrieve]
  32. Prunkard, D., Cottingham, I., Garner, I., Bruce, S., Dalrymple, M., Lasser, G., Bishop, P., and Foster, D. (1996) Nat. Biotech. 14, 867-871 [Medline] [Order article via Infotrieve]
  33. Wise, R. J., Barr, P. J., Wong, P. A., Kiefer, M. C., Brake, A. J., and Kaufman, R. J. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 9378-9382 [Abstract]
  34. Schäfer, W., Stroh, A., Berghöfer, S., Seiler, J., Vey, M., Kruse, M.-L., Kern, H. F., Klenk, H.-D., and Garten, W. (1995) EMBO J. 14, 2424-2435 [Abstract]
  35. Vey, M., Schäfer, W., Berghöfer, S., Klenk, H-D., and Garten, W. (1994) J. Cell Biol. 127, 1829-1847 [Abstract]
  36. Rehemtulla, A., Dorner, A. J., and Kaufman, R. J. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 8235-8239 [Abstract]
  37. Rehemtulla, A., and Kaufman, R. J. (1992) Blood 79, 2349-2355 [Abstract]
  38. Prieto, P. A., Mukerji, P., Kelder, B., Erney, R., Gonzalez, D., Yun, J. S., Smith, D, F., Moremen, K. W., Nardelli, C., Pierce, M., Li, Y., Chen, X., Wagner, T. E., Cummings, R. D., and Kopchick, J. J. (1995) J. Biol. Chem. 270, 29515-29519 [Abstract/Free Full Text]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.